00882 TIANJIN DEV
- 1.780
- -0.010-0.56%
TIANJIN DEV News
Tianjin Development Holdings Books Lower Profit, Revenue in H1
tianjin dev (00882.HK) has a net profit of approximately 0.288 billion Hong Kong dollars for the interim period, with an interim dividend of 5.18 Hong Kong cents.
Great Connection August 29th, Tianjin Dev (00882.HK) announced that for the six months ended June 30, 2024, the company's income was approximately HK$1,820,260,000 (same period last year: HK$1,830,477,000). The attributable profit to owners of the company was approximately HK$288,077,000 (same period last year: HK$371,509,000). Basic earnings per share were 26.85 HK cents, with an interim dividend of 5.18 HK cents per share (same period last year: 3.45 HK cents per share).
Express News | Tianjin Development Holdings Ltd - Hy Revenue HK$1.82 Bln
Express News | Tianjin Development - Interim Dividend of HK5.18 Cents per Share
天津發展：截至二零二四年六月三十日止六個月之中期業績公告
Tianjin Lisheng Pharmaceutical's H1 Attributable Profit, Revenue Grow
Tianjin Dev (00882.HK): tianjin lisheng pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.
On August 23, Tianjin Development (00882.HK) announced that Tianjin Lisheng Pharmaceutical (002393.SZ) achieved revenue of 0.745 billion yuan (RMB) in the first half of 2024, a year-on-year increase of 13.25%; the net income attributable to shareholders of Tianjin Lisheng Pharmaceutical was 0.102 billion yuan, a year-on-year increase of 13.50%; and the basic earnings per share was 0.40 yuan.
Express News | Tianjin Development - Hy Total Operating Income for Tianjin Lisheng Pharmaceutical RMB744.6 Mln Vs RMB657.5 Mln
Express News | Tianjin Development Holdings Ltd - Hy Net Profit for Tianjin Lisheng Pharmaceutical of RMB101.3 Mln
TIANJIN DEV: Unaudited Financial Results for the six months ended 30 June 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Board of directors of Tianjin Dev (00882.HK) held a meeting on August 29 to consider and approve the mid-term performance.
Tianjin Dev (00882.HK) announced that it will hold a board of directors meeting on Thursday, August 29, 2024 to consider and approve, among other matters, the announcement of the Company and its subsidiaries' interim results for the six months ended June 30, 2024, and to consider the distribution of interim dividends (if any).
TIANJIN DEV: Date of Board Meeting
Tianjin Development (00882.HK) subsidiary intends to sell 24.65% equity of Tianjin Tianbian Pharmaceutical for 120 million yuan.
On June 28, Gelonhui reported that Tianjin Dev (00882.HK) announced the sale of 24.65% equity in Tianjin Tianbian Pharmaceutical Co., Ltd. On June 28, 2024, Tianjin Lisheng Pharmaceutical and the final winning bidder, Grandpharma (China), entered into a property transaction contract for the sale of the shares at a total price of 120 million yuan. After the completion of the sale, the Group will no longer hold any equity in Tianjin Tianbian. Tianjin Tianbian is a limited liability company established in China, mainly engaged in the production, processing, sales of Chinese and Western medicines, chemical drugs, active pharmaceutical ingredients, trial drugs, biological pharmaceuticals, related services, and the provision of medical information consulting.
Express News | Tianjin Development - Deal for RMB120.3 Mln
Express News | Tianjin Development Holdings Ltd - Disposal of 24.65% Equity Interest in Tianjin Tanabe Seiyaku Co., Ltd
Lisheng Pharmaceutical Avails of 92-Day Structured Deposit Product
Tianjin Dev (00882.HK) subscribed to 150 million yuan of wealth management products.
On June 11, Gelunhui reported that Tianjin Dev (00882.HK) announced that on June 11, 2024, Tianjin Lisheng Pharmaceutical and CBHB signed a second CBHB Wealth Management Agreement to subscribe for structured deposits with a principal amount of RMB 150 million.
Tianjin Dev (00882): Tianjin Lisheng Pharmaceutical subscribes to a total principal amount of 210 million yuan of structured deposits.
Tianjin DEV (00882) announced that on April 30, 2024, its indirectly non-wholly subsidiary Tianjin Lisheng Pharmaceutical and CBHB signed the first CBHB wealth management agreement to subscribe to structured deposits with a principal amount of RMB 60 million. On June 11, 2024, Lisheng Pharmaceutical and CBHB signed the second CBHB wealth management agreement to subscribe to structured deposits with a principal amount of RMB 150 million.
Express News | Tianjin Development - Lisheng Pharmaceutical to Subscribe for Structured Deposit of RMB150 Mln
Tianjin Development (00882.HK) subsidiary plans to sell 24.65% of Tianjin Tanabe Pharmaceutical's shares
Gelonghui, May 10 | Tianjin Development (00882.HK) announced that Lisheng Pharmaceutical (an indirect non-wholly-owned subsidiary of the company) plans to sell all 24.65% of its shares in Tianjin Tianbian through a public listing and sale process. The minimum listing price for the potential sale is RMB 120 million. Tianjin Tanabe is a limited company established in China. It is mainly engaged in the production, processing and sale of Chinese and Western medicines, chemicals, APIs, reagents, biopharmaceuticals and related services, as well as providing pharmaceutical information consultation. The potential sale is in line with Lisheng Pharmaceuticals' overall strategic plan. The Board believes that potential sales matters (if implemented) will improve
Analysis
Price Target
No Data
